Egret Therapeutics Appoints Dr. Geoffrey Ling to Scientific Advisory Board - Advancing its Mission to Address Critical Military Health Needs

Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation following acute injuries

NEW YORK, July 14, 2025 /PRNewswire/ -- Egret Therapeutics today announced the appointment of Dr. Geoffrey Ling, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Ling, a renowned neurologist, Johns Hopkins professor, and former founding director of DARPA's Biological Technologies Office, joins Egret as the company intensifies its commitment to developing therapies for conditions with urgent military relevance, including traumatic brain injury (TBI) and spinal cord injury (SCI).

Dr. Ling is a professor at Johns Hopkins University and the Uniformed Services University of the Health Sciences, and a retired U.S. Army colonel recognized as one of the nation's foremost experts on TBI in military settings. He has led groundbreaking research at DARPA, including the PREVENT program for blast-related brain injury and the Revolutionizing Prostheses initiative for brain-controlled prosthetic limbs. His career spans frontline neurocritical care in combat zones, high-level advisory roles in federal health innovation, and more than 150 scientific publications.

"The addition of Dr. Ling to Egret's team marks a pivotal step as the company sharpens its vision to address the unique health demands faced by military personnel," said Dr. Daniel Chai, Co-Founder of Egret Therapeutics. While Egret's lead program targets acute ischemic stroke, the company's broader mission is to mitigate secondary injury following acute insults—whether from ischemia or trauma—across both neurological and non-neurological conditions. This includes high-impact areas such as heart attack, where preserving tissue structure and function is critical to long-term recovery.

"Egret Therapeutics is on the verge of revolutionizing how we care for service members and civilians alike who suffer devastating injuries," said Dr. Geoffrey Ling. "The company's approach to preserving tissue after acute trauma could be a game-changer for military medicine. I am honored to join Egret's SAB and excited to help accelerate the development of therapies that directly address the needs of those who protect our nation."

Vedik Navale, Chief of Staff at Egret Therapeutics, commented, "Having Dr. Ling join our Scientific Advisory Board is a tremendous honor and a testament to Egret's sharpened mission. His unparalleled expertise in military medicine and neurotrauma will accelerate our efforts to bring transformative therapies to those who need them most."

About Egret Therapeutics

Egret Therapeutics is a clinical stage biotechnology company focused on developing therapies that modulate innate immunity to preserve normal tissue structure and function following acute injury. Egret's platform is designed to address the stereotyped mechanisms responsible for secondary injury across acute injuries that drive long-term disability. The company is pursuing clinical indications in neurology, cardiovascular health, trauma and spine-related conditions.

SOURCE Turret Capital Management